TY - JOUR
T1 - Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
T2 - A position statement of the acute leukemia working party of the European society for blood and marrow transplantation
AU - Giebel, Sebastian
AU - Czyz, Anna
AU - Ottmann, Oliver
AU - Baron, Frederic
AU - Brissot, Eolia
AU - Ciceri, Fabio
AU - Cornelissen, Jan J.
AU - Esteve, Jordi
AU - Gorin, Norbert Claude
AU - Savani, Bipin
AU - Schmid, Christoph
AU - Mohty, Mohamad
AU - Nagler, Arnon
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved overall outcomes; however,a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was demonstrated to reduce the risk of relapse in a large retrospective study and,therefore,should be considered a valuable option. This consensus paper,written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation,presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the choice of TKI,treatment timing,and dosage. It is hoped that these recommendations will become the state of art in this field and,more importantly,lead to a reduction of Ph-positive ALL relapse after alloHSCT. Cancer 2016;122:2941-51. VC 2016 American Cancer Society.
AB - Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved overall outcomes; however,a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was demonstrated to reduce the risk of relapse in a large retrospective study and,therefore,should be considered a valuable option. This consensus paper,written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation,presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the choice of TKI,treatment timing,and dosage. It is hoped that these recommendations will become the state of art in this field and,more importantly,lead to a reduction of Ph-positive ALL relapse after alloHSCT. Cancer 2016;122:2941-51. VC 2016 American Cancer Society.
KW - Allogeneic hematopoietic stem cell transplantation
KW - Dasatinib
KW - Imatinib
KW - Maintenance therapy
KW - Nilotinib
KW - Philadelphia chromosome-positive acute lymphoblastic leukemia
KW - Recommendations
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84992364335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992364335&partnerID=8YFLogxK
U2 - 10.1002/cncr.30130
DO - 10.1002/cncr.30130
M3 - Review article
AN - SCOPUS:84992364335
VL - 122
SP - 2941
EP - 2951
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 19
ER -